A recently published systematic literature review sought to compare the effects of down-titration of biologics compared with standard dosing on clinical efficacy and health-related quality of life, and to evaluate the impact of decreased doses on the cost of RA treatment.
Biologic therapies have resulted in better treatment of rheumatoid arthritis (RA), and have allowed many patients to achieve remission. The efficacy of these therapies has allowed clinicians to consider down-titration (also referred to as dose reduction or dose tapering) for patients who have achieved remission or low disease activity (LDA), though rheumatology guidelines in the United States, Asia, and Europe all acknowledge the fact that the level of evidence guiding down-titration is moderate to very low.
A recently published systematic literature review sought to compare the effects of down-titration of biologics compared with standard dosing on clinical efficacy and health-related quality of life (HRQL), and to evaluate the impact of decreased doses on the cost of RA treatment.
The investigators, led by Chak Sing Lau, MD, conducted an electronic literature search of English-language references published from January 2000 to February 2015. Randomized controlled trials, non-randomized controlled trials, observational studies, and pharmacogenomics studies were eligible for inclusion and screened for risk of bias. The studies that qualified for inclusion evaluated adalimumab, certolizumab, etanercept, infliximab, and rituximab:
In terms of economic outcomes, most studies reported a decrease in cost with down-titration. One retrospective US cost analysis found, however, that patients with a decreased dose had a significantly higher number of inpatient admissions, physician visits, laboratory and diagnostic tests, and prescriptions.
Based on these findings, the authors concluded that down-titration can be successful in some patients with RA, and that down-titration generally decreases costs. However, because some patients are unable to retain remission or LDA after having changed their treatment dosage, care must be exercised so that these patients do not experience joint damage.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.